BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 11757204)

  • 21. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
    Sakurai T
    Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of hypercalcemia of malignancy with bisphosphonates.
    Berenson JR
    Semin Oncol; 2002 Dec; 29(6 Suppl 21):12-8. PubMed ID: 12584690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in supportive care of patients with cancer and bone metastases: nursing implications of zoledronic acid.
    Maxwell C; Swift R; Goode M; Doane L; Rogers M
    Clin J Oncol Nurs; 2003; 7(4):403-8. PubMed ID: 12929273
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Zoledronic acid.
    Cheer SM; Noble S
    Drugs; 2001; 61(6):799-805; discussion 806. PubMed ID: 11398911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
    Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
    J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials.
    Major P; Lortholary A; Hon J; Abdi E; Mills G; Menssen HD; Yunus F; Bell R; Body J; Quebe-Fehling E; Seaman J
    J Clin Oncol; 2001 Jan; 19(2):558-67. PubMed ID: 11208851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hypercalcemia of malignancy.
    Body JJ
    Semin Nephrol; 2004 Jan; 24(1):48-54. PubMed ID: 14730509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone disease in myeloma.
    Berenson JR
    Curr Treat Options Oncol; 2001 Jun; 2(3):271-83. PubMed ID: 12057127
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Zoledronic acid: multiplicity of use across the cancer continuum.
    Lipton A
    Expert Rev Anticancer Ther; 2011 Jul; 11(7):999-1012. PubMed ID: 21806323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
    Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
    Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Zoledronic acid in cancer patients with bone metastases: results of Phase I and II trials.
    Berenson JR
    Semin Oncol; 2001 Apr; 28(2 Suppl 6):25-34. PubMed ID: 11346862
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zoledronic acid. A bisphosphonate for hypercalcemia of malignancy and osteolytic metastases.
    Massaro AM
    Cancer Pract; 2002; 10(4):219-21. PubMed ID: 12100107
    [No Abstract]   [Full Text] [Related]  

  • 33. A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease.
    Berenson JR; Vescio R; Henick K; Nishikubo C; Rettig M; Swift RA; Conde F; Von Teichert JM
    Cancer; 2001 Jan; 91(1):144-54. PubMed ID: 11148571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.
    Pozzi S; Raje N
    Oncologist; 2011; 16(5):651-62. PubMed ID: 21493759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Bisphosphonates and bone metastases].
    Lortholary A; Jadaud E; Berthaud P
    Bull Cancer; 1999 Sep; 86(9):732-8. PubMed ID: 10519966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bisphosphonates in the treatment of skeletal metastases.
    Conte P; Coleman R
    Semin Oncol; 2004 Oct; 31(5 Suppl 10):59-63. PubMed ID: 15490377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aetiology of bone disease and the role of bisphosphonates in multiple myeloma.
    Ashcroft AJ; Davies FE; Morgan GJ
    Lancet Oncol; 2003 May; 4(5):284-92. PubMed ID: 12732166
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bisphosphonates: clinical experience.
    Coleman RE
    Oncologist; 2004; 9 Suppl 4():14-27. PubMed ID: 15459426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pamidronate causes apoptosis of plasma cells in vivo in patients with multiple myeloma.
    Gordon S; Helfrich MH; Sati HI; Greaves M; Ralston SH; Culligan DJ; Soutar RL; Rogers MJ
    Br J Haematol; 2002 Nov; 119(2):475-83. PubMed ID: 12406088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.